WallStreetZenWallStreetZen

NASDAQ: GLTO
Galecto Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their GLTO stock forecasts and price targets.

Forecast return on equity

Is GLTO forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is GLTO forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

GLTO revenue forecast

What is GLTO's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$27.8M
Avg 2 year Forecast
$35.3M
Avg 3 year Forecast
$104.7M

GLTO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLTO$0.72N/AN/A
BIVI$0.49$5.00+924.59%Buy
NKGN$0.86N/AN/A
TCRT$1.23N/AN/A
VINC$0.90N/AN/A

Galecto Stock Forecast FAQ

What is GLTO's revenue growth forecast for 2027-2029?

(NASDAQ: GLTO) Galecto's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Galecto's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast GLTO's revenue for 2027 to be $754,221,005, with the lowest GLTO revenue forecast at $754,221,005, and the highest GLTO revenue forecast at $754,221,005. On average, 1 Wall Street analysts forecast GLTO's revenue for 2028 to be $957,078,204, with the lowest GLTO revenue forecast at $957,078,204, and the highest GLTO revenue forecast at $957,078,204.

In 2029, GLTO is forecast to generate $2,838,699,376 in revenue, with the lowest revenue forecast at $2,838,699,376 and the highest revenue forecast at $2,838,699,376.

If you're new to stock investing, here's how to buy Galecto stock.

What is GLTO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GLTO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GLTO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GLTO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.